Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Alphamab Oncology ( (HK:9966) ) is now available.
Alphamab Oncology has announced the resignation of joint company secretary and authorized representative Cheng Qiulan, effective 8 April 2026, citing other work commitments and noting no disagreement with the board. Cheng’s departure triggers a reshuffle in the company’s governance team but is presented as orderly and non-contentious.
The board has appointed Jiang Rui as joint company secretary and authorized representative from the same date, alongside existing joint company secretary Chan Lok Yee, and is seeking a waiver from strict compliance with Hong Kong Listing Rules 3.28 and 8.17 due to Jiang’s non-standard qualifications. The company argues Jiang’s extensive internal control, audit and biopharmaceutical experience makes her suitable for the role, underscoring a focus on strengthening corporate governance and maintaining ongoing regulatory compliance despite the formal waiver requirement.
The most recent analyst rating on (HK:9966) stock is a Buy with a HK$9.60 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a Cayman Islands-incorporated biopharmaceutical group focused on oncology, with its shares listed on the Hong Kong Stock Exchange under stock code 9966. The company develops cancer therapies and operates within the broader biopharmaceutical industry, emphasizing research-driven growth and compliance with Hong Kong listing requirements.
Average Trading Volume: 1,404,231
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.81B
Find detailed analytics on 9966 stock on TipRanks’ Stock Analysis page.